Based in Cumberland, Maryland, RS BioTherapeutics is a life-sciences company focused on developing medicines for people with pulmonary inflammation. Its lead investigational compound, RSBT-001, is being studied as a steroid-free approach to serious respiratory disease, with development informed by a council of prominent pulmonary specialists.
GSK plcGSK plc is a focused biopharmaceutical company that discovers, develops and delivers medicines and vaccines. Its research and development concentrates on respiratory, immunology and inflammation; oncology; HIV; and infectious diseases, with R&D hubs in the UK, US and Belgium and a network spanning Europe, North America and Asia.PENNSYLVANIA, PA
Respair, IncBorn from University of Pittsburgh clinical research, Pittsburgh-based Respair develops airway devices for ventilated patients, beginning with RelianceET, a breathing tube designed to replace the conventional inflatable cuff with soft baffles that seal the airway without added pressure. Founded by physicians Carl Snyderman and Garrett Coyan, the company brings surgeons, engineers, and entrepreneurs together to address ventilator-associated complications. Respair completed hundreds of benchtop tests and received a Phase I SBIR award from the NIH while advancing the device toward regulatory submission.PITTSBURGH, PA
Globin SolutionsFounded by University of Pittsburgh physician-scientists in 2017, Globin Solutions develops recombinant heme-protein therapeutics, including candidates intended to counter carbon monoxide poisoning. The Baltimore company’s proprietary yeast-based platform produces complex heme proteins at more than 95% purity and also supports research into artificial blood substitutes. Its neuroglobin candidate has received FDA Orphan Drug Designation, while the company advances three therapeutic programs toward clinical development.325414PITTSBURGH, PA
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA